{"name":"4D Molecular Therapeutics","slug":"4d-molecular","ticker":"FDMT","exchange":"NASDAQ","domain":"4dmoleculartherapeutics.com","description":"4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille,","hq":"Emeryville, CA","founded":0,"employees":"196","ceo":"David Kirn","sector":"Gene Therapy / Ophthalmology","stockPrice":9.89,"stockChange":-0.56,"stockChangePercent":-5.36,"marketCap":"$517M","metrics":{"revenue":88242000,"revenueGrowth":21664.3,"grossMargin":-145.7,"rdSpend":0,"netIncome":-140109000,"cash":390892000,"dividendYield":0,"peRatio":-2.7,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"4D-110 patent cliff ($0.0B at risk)","drug":"4D-110","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"4D-110","genericName":"4D-110","slug":"4d-110","indication":"Other","status":"phase_1"},{"name":"4D-310","genericName":"4D-310","slug":"4d-310","indication":"Other","status":"phase_1"},{"name":"4D-710","genericName":"4D-710","slug":"4d-710","indication":"Cystic fibrosis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Aflibercept IVT","genericName":"Aflibercept IVT","slug":"aflibercept-ivt","indication":"Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration)","status":"phase_2"}]}],"pipeline":[{"name":"4D-110","genericName":"4D-110","slug":"4d-110","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"4D-310","genericName":"4D-310","slug":"4d-310","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"4D-710","genericName":"4D-710","slug":"4d-710","phase":"phase_2","mechanism":"4D-710 is a gene therapy that uses an adeno-associated virus to deliver a functional copy of the CFTR gene to the lungs, correcting the underlying genetic defect in cystic fibrosis.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"Aflibercept IVT","genericName":"Aflibercept IVT","slug":"aflibercept-ivt","phase":"phase_2","mechanism":"Aflibercept IVT is a vascular endothelial growth factor (VEGF) trap that binds and neutralizes VEGF and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular permeability.","indications":["Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"4D Molecular Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"FDMT reported its Q4 and FY 2023 financial results, with a net loss of $43.1 million and $173.4 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"regulatory","headline":"4D Molecular Therapeutics Announces FDA Clearance of IND for 4D-110","summary":"FDMT announced that the FDA has cleared the IND for its lead product, 4D-110, for the treatment of inherited retinal diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-10","type":"deal","headline":"4D Molecular Therapeutics Announces Collaboration with Regeneron Pharmaceuticals","summary":"FDMT announced a collaboration with Regeneron Pharmaceuticals to develop gene therapies for inherited retinal diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxPMk40OHRyNlhSMXMzM1RyZ19vSWp0eWs4MEZoR0lCMm02UkJ4X2VDYkM4NFg1dDlTbGVkSTNoN2NJMFZQN19PRkN2Zk1oQzh2TzA1bS1hWk5SajhxcFpTOGdFSnZCcDBjSjc0akJaU3dvTE5yV19qRG1DcjlQWUl4NDNQbUk1LVFiclZGaUJMc2Z6M05vYTJNOXJxQ3h0cjRod2hac21yWkhQQmoxbjFMZXByalBXeE5mUXFYVi15QWpIWkRTMFdpYVA3UXIwUHpWN1JzOHFKdFpHMzRYeDJuZnNUQ1IwQjhOc1V0NWFEaXU0cDFBSFpDa25MMFBfWHgtcnhrN1luUHB6cmNqZGNlajdtbnlTYVNITFhoZXVKZld6Slh0VDA1NzI0RTkwcjN6b1pNN2FxaUoyS0c0M3ZqbXBOaG0?oc=5","date":"2026-03-21","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acriv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPVUdTWU9tYnM3NmN0YS10YUFsMWRpa29CWFVNZUVBN2lGdXBNNFBjS0VycXNNSGwyYmJGSmd5R0dlRHNiOHAxMzZVZG4zcEFYcDZsa0tEUW53bnppNEdqQUNNZWk4QTNiMUY4WHdlWGluOWhRVmh2UHRtVEN2QXkycWRxeUdOWG5HZEYtcXU2SGxLX0dVcU53eC1Nb3M4TFVUWHpiNlQxT3JOOHNDci1ocnFYLS1oNThDbVB0RUViMU9rQUxxZzZ3N2YxeUJCQ1NDTzNXMlBBVno2MmVPTU5KVTJyeE9obUtndXJB?oc=5","date":"2026-03-20","type":"pipeline","source":"The Globe and Mail","summary":"4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail","headline":"4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-19","type":"earnings","source":"simplywall.st","summary":"4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st","headline":"4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative","sentiment":"neutral"},{"date":"2026-03-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNTFUxSnNPV0J1UzVneVFveEhnbDh6ei1oM3lzSi04MmtiQ3hBNVE1Q0RtWlVTblRxVjlzdEttWlJiYzhkVjVXZl80SkwwLUEzMHlydklNM0hxY2ZuYVNJQnpKdEhyQnJMb2p5cWpEaG9nV1NIWExKT2QzOGs0cE40SVlNOEN2eFV3QmpzQmdyVjVhSHVXSnFydDVOaFZBdnpsZ1VDS2NUeUstRngwZjQyMHd4N2Ewc1hhSWJOcHI0Yw?oc=5","date":"2025-12-19","type":"trial","source":"Seeking Alpha","summary":"4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha","headline":"4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNamhFVjBWekF2Mjc3cHpia0tNdkhXUlM3YkgtcHZ1NkNsMmtFSnNsRGZmNFM4a29iTUVKLUdjSWtHUjhReVdyd2RMLUdiQkQwVWpfc1pkS0FUVXo0d1NkbWhET2JtMHRoMnRTVi1oUjhLdWQyaWpKYWtscjlRRS1qNmZOUHU2MDhXdUdwWDg1UE5PTFMtWTdGYlJnZXJwbjVRc3hqaVFuNkJ1NjdUTGZPY19NaTUzdzdyZ3dPaEdaVDFlZ2lKNTBrclFSUml0NFJEWE44aWl2X1dZME9ZeUJITHQzZmVLb0JiWFJ6WC1ydi1BM1JLOWl2cWpweHRTdw?oc=5","date":"2025-12-19","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE96T2JLMV94YWZ4bUJYbnBLaFRRVXEtWlNDZmdPZFZkLUNvS2ZXczhPZDN2NXJLVkFEZW50alltMUNxQ2tpOG5VeWdtRUJ1enNDT2N6RW5SYlM?oc=5","date":"2025-12-01","type":"pipeline","source":"StocksToTrade","summary":"Top Biotech Penny Stocks to Watch Out for in 2025 - StocksToTrade","headline":"Top Biotech Penny Stocks to Watch Out for in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPVGpuYndVWTVPVV8tbEVNYWEtUGpiQ0FzNE55WGlkTlZ4QnpGNXhISGVuQlhDdlpHdG8xTmJ1RjZTbGViZWtPYmhvMGQxaU8wa0dGVENLY0g5blhldmJXQjQxS1BBVlFlWmdqZlFpRkxIY1I0NW9JbFdOUEtITXZSZXRJWFhwY0JHN2dsZm5YZ2c1dHdWU0NGQnRqemF3VUlGSng1cUs4WXhYYWFFZ0ZTR2hDdC1PZXJqd3hZUHo0SVdoQ1Bzc21YLUQ0N20zdUhOaDdVcmMyZjZtOG9VRDlDMlFHdkZyTnA3TzM0NEkta9IB9AFBVV95cUxONktLS0pnWGJCQ3lNWGpzWEJpanZKMnMzYVBrSkJqU3NXMXFzV0NpRTBxSHhrdGEtNUxUNUUyZ3M5amVyTVpZY0d2OVp6MmhabVFvNXhHcWswS01WM3pJRXY1eVFlRzV5YjNObW5CT0haZDN0c0NXNlRpZlVPeTJHT1FscXBUbl9wTU1TbFQzcHFzeFpsVVlIaWw2ZUxiNjNweE8wajRnajh5XzFTZmY5SktocjFXRlo2dUhWenFpVHduZWgwdjJfWFMtVUJSZzZHN2J3RXVSV1NCN21FVUtHYjFpdUthUWl5cU9sREhLbndpcEc1?oc=5","date":"2025-11-12","type":"pipeline","source":"simplywall.st","summary":"Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st","headline":"Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdjdyaVRlSHNDLUFTamUxVFBwNVZpUGZsSFJnZEh1ejAwVXNzemFSTFZQWEROSnRNYjdLUmJHbTk0RVhIbjRDNVQwVlBuWnR2U0UtRWYtQUItT1NuMTljTXlBMUFlRXVNcFBLMVFDcVIxSzJxaF9Vb0I5MmFtaEVzSG9qcVhfZ1NmaHJ1NDVDdnJuR3NucVotSVEtNjVTRThqT2pFSkJmeUVUdw?oc=5","date":"2025-10-31","type":"trial","source":"The Pharma Letter","summary":"4DMT secures $85 million Otsuka deal to fund Phase III program - The Pharma Letter","headline":"4DMT secures $85 million Otsuka deal to fund Phase III program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQcUU3eGRDQjNLYjM2M0I1OEF2ZG1ZaFBkVkxWUmFPQ0M3TlhqNXJZOTM5WmZraTJRNkxMS2tTZUFLbGY5RnAwMUN4enFlc19aUUJqRHd6LUtJaU5taGtlcTdUUkhlazBsTzc1SDBYM0JlSVRZN2dZbjBfQXZjOENodkN2czJIYTFnNklOY2xPN2hFOEJTT0NKTG9uZVc5Y2FZa3ZWdDdhZlZOUS0tTVFjZzl3WFROSDhmOU9jaXhSTWxGdk5WWnBxcFZscXZEQUI0Zk5VRGtEOFhuUU1iNmxSbTZQekItdk5CekttR2YxWkVWTE1aY0EwV3NnZUp6THVfS2NMYUZYVUVhY1Z0YWxhUlNzWF9YN3RTWkZnMS1EZ2dNQlFoNDZoWk5wWTU4Zi1ZdURsMnFhcw?oc=5","date":"2025-10-30","type":"deal","source":"GlobeNewswire","summary":"4DMT Announces Exclusive License Agreement with Otsuka - GlobeNewswire","headline":"4DMT Announces Exclusive License Agreement with Otsuka","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNS1dZdnBBYUEwNXVXQ04zeWxYZndYV0VzV1licFdGU3hyVkx3N0RMQTR4akZzdkYwY3ZLaVhqMm1DMXJtQWk0SEFzeF9aY1hkVnFJV080TURFN2dXbFlteWV1UHM0dDdOaGdDc05lNVg0RWxWMzVTYnVDUGw0VE5haTdNcnZSeTlCTE8talhpTkdaY0lHUGI1dGhIaHNfbzhhdVFXcEdiSHR6N0phS043ZDRLdGNqdmRyRFFBQThNWjBWa2J5SWxuaGY5SW5HeUVXMW9QdjZaOGQ2Q25vZE5uRFJvVDlRWm5hYVpFd0RBcFFodmQ3LU5ZYWZqc1cxRjMtY25nN0NBOXRtRmlPVURXa215Wlk0QTV0aTNpY0FjZDFmY0h4MU9yZnhVRTZCazQ?oc=5","date":"2023-07-10","type":"deal","source":"PR Newswire","summary":"Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - PR Newswire","headline":"Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 V","sentiment":"neutral"}],"patents":[{"drugName":"4D-110","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Spark Therapeutics","Editas Medicine","Nightstar Therapeutics"],"therapeuticFocus":["Ophthalmology","Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":85209000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":85209000,"period":"2025-12-31"},{"value":37000,"period":"2024-12-31"},{"value":37000,"period":"2024-12-31"},{"value":20723000,"period":"2023-12-31"},{"value":20723000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":195696000,"rdSpendHistory":[{"period":"2025-12-31","value":195696000},{"period":"2024-12-31","value":141299000},{"period":"2023-12-31","value":97096000},{"period":"2022-12-31","value":80253000}],"sgaSpend":49060000,"operatingIncome":-159547000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-159547000},{"period":"2024-12-31","value":-187841000},{"period":"2023-12-31","value":-112867000},{"period":"2022-12-31","value":-110032000}],"netIncome":-140109000,"netIncomeHistory":[{"period":"2025-12-31","value":-140109000},{"period":"2024-12-31","value":-160868000},{"period":"2023-12-31","value":-100837000},{"period":"2022-12-31","value":-107494000}],"eps":-2.98,"epsHistory":[{"period":"2024-12-31","value":-2.98},{"period":"2023-12-31","value":-2.58},{"period":"2022-12-31","value":-3.32},{"period":"2021-12-31","value":-2.57}],"cash":60241000,"cashHistory":[{"period":"2025-12-31","value":60241000},{"period":"2024-12-31","value":149336000},{"period":"2023-12-31","value":249108000},{"period":"2022-12-31","value":52351000}],"totalAssets":566711000,"totalLiabilities":61047000,"totalDebt":21413000,"equity":505664000,"operatingCashflow":-109082000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-109082000},{"period":"2024-12-31","value":-134585000},{"period":"2023-12-31","value":-75792000},{"period":"2022-12-31","value":-86685000}],"capex":-536000,"capexHistory":[{"period":"2025-12-31","value":-536000},{"period":"2024-12-31","value":-3786000},{"period":"2023-12-31","value":-2771000},{"period":"2022-12-31","value":-11536000}],"freeCashflow":-109618000,"dividendsPaid":null,"buybacks":null,"employees":196,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":12767000,"ebit":14715000,"ebitda":16695000,"period":"2025-12-31","revenue":85090000,"epsBasic":null,"netIncome":19397000,"rdExpense":57608000,"epsDiluted":null,"grossProfit":null,"operatingIncome":14715000},{"sga":11837000,"ebit":-61185000,"ebitda":-59182000,"period":"2025-09-30","revenue":90000,"epsBasic":-1.01,"netIncome":-56876000,"rdExpense":49438000,"epsDiluted":-1.01,"grossProfit":null,"operatingIncome":-61185000},{"sga":11520000,"ebit":-59456000,"ebitda":-57568000,"period":"2025-06-30","revenue":15000,"epsBasic":-0.98,"netIncome":-54658000,"rdExpense":47951000,"epsDiluted":-0.98,"grossProfit":null,"operatingIncome":-59456000},{"sga":12936000,"ebit":-53621000,"ebitda":-51867000,"period":"2025-03-31","revenue":14000,"epsBasic":-0.86,"netIncome":-47972000,"rdExpense":40699000,"epsDiluted":-0.86,"grossProfit":null,"operatingIncome":-53621000},{"sga":13031000,"ebit":-56117000,"ebitda":-54333000,"period":"2024-12-31","revenue":1000,"epsBasic":null,"netIncome":-49671000,"rdExpense":43087000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-56117000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.79,"netIncome":null,"rdExpense":null,"epsDiluted":-0.79,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":9.89,"previousClose":10.45,"fiftyTwoWeekHigh":12.34,"fiftyTwoWeekLow":3.02,"fiftyTwoWeekRange":"3.02 - 12.34","fiftyDayAverage":9.45,"twoHundredDayAverage":8.87,"beta":2.76,"enterpriseValue":175929856,"forwardPE":-2.7,"priceToBook":1.14,"priceToSales":5.86,"enterpriseToRevenue":1.99,"enterpriseToEbitda":-1.03,"pegRatio":0,"ebitda":-171434000,"ebitdaMargin":-194.3,"freeCashflow":-69357248,"operatingCashflow":-129449000,"totalDebt":20535000,"debtToEquity":4.5,"currentRatio":9.34,"returnOnAssets":-21.4,"returnOnEquity":-34.9,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":28.22,"targetHighPrice":36,"targetLowPrice":17,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.5,"institutionHeldPercent":98.8,"sharesOutstanding":52276254,"floatShares":36485166,"sharesShort":11990069,"shortRatio":16.77,"shortPercentOfFloat":22.9,"epsTrailing":-2.57,"epsForward":-3.72,"revenuePerShare":1.45,"bookValue":8.64,"officers":[{"age":64,"name":"Dr. John F. Milligan Ph.D.","title":"Executive Chairman"},{"age":62,"name":"Dr. David H. Kirn M.D.","title":"Co-Founder, President, CEO & Director"},{"age":49,"name":"Mr. Kristian  Humer M.B.A.","title":"CFO and Principal Financial & Accounting Officer"},{"age":62,"name":"Dr. Fariborz  Kamal Ph.D.","title":"Chief Technical Advisor"},{"age":50,"name":"Ms. Theresa  Janke","title":"Co-Founder & Chief of Staff"},{"age":null,"name":"Julian  Pei","title":"Head of Investor Relations & Corporate Finance"},{"age":null,"name":"Dr. Katy  Barglow Ph.D.","title":"Chief Technical Officer"},{"age":53,"name":"Dr. Scott P. Bizily J.D., Ph.D.","title":"Chief Legal Officer & Corporate Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.4dmoleculartherapeutics.com","phone":"510 505 2680"}}